Sphera Funds Management LTD. Buys New Position in Savara Inc (SVRA)

Sphera Funds Management LTD. bought a new position in shares of Savara Inc (NASDAQ:SVRA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 209,596 shares of the company’s stock, valued at approximately $2,339,000. Sphera Funds Management LTD. owned 0.60% of Savara as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Savara during the second quarter worth approximately $104,000. Alliancebernstein L.P. purchased a new stake in shares of Savara during the third quarter worth approximately $118,000. UBS Group AG increased its stake in shares of Savara by 1,012.8% during the first quarter. UBS Group AG now owns 14,556 shares of the company’s stock worth $133,000 after buying an additional 13,248 shares during the period. MetLife Investment Advisors LLC purchased a new stake in shares of Savara during the second quarter worth approximately $148,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Savara during the third quarter worth approximately $198,000. Hedge funds and other institutional investors own 51.14% of the company’s stock.

Shares of Savara stock opened at $7.63 on Friday. The company has a market capitalization of $276.82 million, a price-to-earnings ratio of -4.34 and a beta of -0.02. Savara Inc has a 52 week low of $7.61 and a 52 week high of $17.19. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.23 and a current ratio of 10.23.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). Analysts anticipate that Savara Inc will post -1.42 EPS for the current fiscal year.

A number of analysts recently weighed in on SVRA shares. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Savara in a research note on Friday, August 10th. Roth Capital started coverage on shares of Savara in a research note on Monday, August 13th. They set a “neutral” rating and a $12.00 target price on the stock. Canaccord Genuity set a $25.00 target price on shares of Savara and gave the stock a “buy” rating in a research note on Tuesday, August 14th. BidaskClub lowered shares of Savara from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Finally, Zacks Investment Research lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Thursday, August 16th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Savara currently has an average rating of “Hold” and a consensus price target of $26.80.

In other Savara news, CFO David L. Lowrance sold 18,480 shares of the stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $9.22, for a total value of $170,385.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 6.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Sphera Funds Management LTD. Buys New Position in Savara Inc (SVRA)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/12/08/sphera-funds-management-ltd-buys-new-position-in-savara-inc-svra.html.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading: Penny Stocks, What You Need To Know

Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc (NASDAQ:SVRA).

Institutional Ownership by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply